Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALEX
2023-506859-13-00Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of alectinib in ALK-positive non-small cell lung cancer (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival (PFS) by investigator assessment. Started Jul 2024; status: completed.
02
Drugs
alectinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on 2023-506859-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506859-13-00.